Develops drugs for GI diseases, infectious diseases, and oncology.
Dec 2024Revenue $8.04M/yrExpenses $22.7M/yr
No trendCash runway ≈ 6 months from Dec 2024
Figures by year
When will RedHill Biopharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2024, revenue was $8.04M and expenses $22.7M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $8.04M | $22.7M | −$14.6M |
| Dec 2023 | $6.53M | −$6.10M | $12.6M |
| Dec 2022 | $61.8M | $105M | −$42.8M |
| Dec 2021 | $85.8M | $167M | −$81.1M |
| Dec 2020 | $64.4M | $128M | −$63.7M |
| Dec 2019 | $6.29M | $49.5M | −$43.2M |
| Dec 2018 | $8.36M | $47.7M | −$39.3M |
| Dec 2017 | $4.01M | $56.0M | −$52.0M |
| Dec 2016 | $101K | $30.6M | −$30.5M |
| Dec 2015 | $3.00K | $22.0M | −$22.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.